Amit Munshi's Next-Gen RNA Therapeutics Startup: Thinking Big with $300M+
Amit Munshi, former CEO of Arena Pharmaceuticals, is now leading ReNAgade Therapeutics, a startup focused on next-gen RNA therapeutics. Meanwhile, Indivior has acquired a new nasal spray for opioid overdose, Icosavax is pushing forward with a bivalent RSV-hMPV vaccine, and Ironwood Pharmaceuticals is set to acquire VectivBio in a $1 billion all-cash deal. Quanta Therapeutics has also raised $50.7 million to develop KRAS inhibitors for clinical trials in 2024.